首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >A population-based screening for microalbuminuria among relatives of CKD patients: the Kidney Evaluation and Awareness Program in Sheffield (KEAPS).
【24h】

A population-based screening for microalbuminuria among relatives of CKD patients: the Kidney Evaluation and Awareness Program in Sheffield (KEAPS).

机译:在CKD患者亲属中进行基于人群的微量白蛋白尿筛查:谢菲尔德肾脏评估和意识计划(KEAPS)。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Microalbuminuria has been used to detect subjects at risk of cardiovascular disease and chronic kidney disease (CKD) in patients with diabetes, those with hypertension, and the general population. However, relatives of patients with CKD have not been investigated for microalbuminuria in the United Kingdom. STUDY DESIGN: A cross-sectional study evaluating the prevalence of microalbuminuria in relatives of patients with CKD compared with the general population of Sheffield, England. SETTING & PARTICIPANTS: Participants in the Kidney Evaluation and Awareness Program in Sheffield, a population-based screening program for microalbuminuria. 274 relatives of patients with CKD were studied and compared with an age- and sex-matched control group from the general population. PREDICTOR: Family history of CKD. MEASUREMENT & OUTCOMES: Screening tools included a questionnaire collating information for demographics, lifestyle, and medical and family history of diabetes, hypertension, and CKD. Urine samples were collected for microalbuminuria estimation. Microalbuminuria measurements were obtained by using immunonephelometry. Microalbuminuria thresholds were defined using albumin-creatinine ratio. RESULTS: The prevalence of microalbuminuria was 9.5% in those with a family history of CKD. This was significantly greater than the prevalence of 1.4% in the age- and sex-matched control group with no family history of CKD (P = 0.001). Independent determinants of microalbuminuria in the study population in an adjusted logistic regression model were family history of diabetes (odds ratio [OR], 2.88; 95% confidence interval, 1.17 to 7.04), obesity (OR, 3.29; 95% confidence interval, 1.61 to 6.69), and family history of CKD (OR, 6.96; 95% confidence interval, 3.48 to 13.92). LIMITATIONS: Cross-sectional snapshot analysis, microalbuminuria measured once. CONCLUSIONS: The prevalence of microalbuminuria in relatives of patients with CKD is greater than in an age- and sex-matched control group from the general population. The prognostic value of microalbuminuria in this category of at-risk population remains to be determined in longitudinal studies.
机译:背景:微量白蛋白尿已被用于检测糖尿病患者,高血压患者和普通人群中有心血管疾病和慢性肾脏疾病(CKD)风险的受试者。然而,在英国,尚未对CKD患者的亲属进行微量白蛋白尿的调查。研究设计:一项横断面研究,评估与英国谢菲尔德总人口相比,CKD患者亲属中微量白蛋白尿的患病率。地点和参与者:谢菲尔德肾脏评估和意识计划的参与者,该计划是基于人群的微量白蛋白尿筛查计划。研究了274名CKD患者的亲属,并将其与年龄和性别相匹配的对照组进行比较。预测:CKD的家族史。测量与结果:筛查工具包括一个问卷,该问卷整理了有关人口统计学,生活方式,糖尿病,高血压和CKD的医学和家族史的信息。收集尿液样本用于微量白蛋白尿评估。微量白蛋白尿测量是通过免疫比浊法获得的。使用白蛋白-肌酐比值定义微量白蛋白尿阈值。结果:有CKD家族史的患者中微量白蛋白尿的发生率为9.5%。这明显高于没有CKD家族史的年龄和性别匹配对照组中1.4%的患病率(P = 0.001)。在调整的逻辑回归模型中,研究人群中微量白蛋白尿的独立决定因素是糖尿病家族史(几率[OR]为2.88; 95%置信区间为1.17至7.04),肥胖症(OR为3.29; 95%置信区间为1.61)至6.69)和CKD家族史(OR为6.96; 95%置信区间为3.48至13.92)。局限性:横断面快照分析,微量白蛋白尿测定一次。结论:CKD患者亲属中微量白蛋白尿的患病率高于一般人群中年龄和性别相匹配的对照组。在此类高危人群中,微量白蛋白尿的预后价值尚待纵向研究确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号